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Objective. To evaluate whether a model to predict a failed endometrial biopsy in women with postmenopausal bleeding (PMB)
and a thickened endometrium can reduce costs without compromising diagnostic accuracy.Design, Setting, and Population. Model
based cost-minimization analysis.Methods. A decision analyticmodelwas designed to compare twodiagnostic strategies forwomen
with PMB: (I) attempting office endometrial biopsy and performing outpatient hysteroscopy after failed biopsy and (II) predicted
probability of a failed endometrial biopsy based on patient characteristics to guide the decision for endometrial biopsy or immediate
hysteroscopy. Robustness of assumptions regarding costs was evaluated in sensitivity analyses.Main Outcome Measures. Costs for
the different strategies. Results. At different cut-offs for the predicted probability of failure of an endometrial biopsy, strategy I was
generally less expensive than strategy II. The costs for strategy I were always C 460; the costs for strategy II varied between C 457
and C 475. At a 65% cut-off, a possible saving of C 3 per woman could be achieved. Conclusions. Individualizing the decision to
perform an endometrial biopsy or immediate hysteroscopy in women presenting with postmenopausal bleeding based on patient
characteristics does not increase the efficiency of the diagnostic work-up.
1. Introduction
Postmenopausal bleeding (PMB) is the most common pre-
senting symptom of endometrial cancer and warrants further
investigation [1]. Since the 1990s, endometrial thickness
measured by transvaginal ultrasoundwas introduced to select
women for further invasive diagnostic testing to detect or
rule out endometrial cancer [2–4]. Although the optimal
endometrial thickness cut-off for women with PMB still
remains questionable, at present most guidelines advise an
endometrial thickness cut-off of 4 or 5mm to select patients
for further histological verification [1, 5–10]. Outpatient
endometrial biopsy is the least invasive technique to obtain
material for histological assessment. Pipelle endometrial
biopsy (Pipelle de Cornier, Paris, France) is themost accurate
endometrial sampling device to detect endometrial carci-
noma and endometrial hyperplasia in patients with PMB
[11]. Furthermore, a strategy with endometrial biopsy after
endometrial thicknessmeasurement is themost cost-effective
diagnostic strategy for patients with PMB [12].
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Although endometrial biopsy is the most accurate and
frequently used diagnostic procedure, it has some major
drawbacks in clinical practice. In 12–21% of cases, endome-
trial sampling fails due to technical reasons [13–15] and in 7–
68% of cases the number of tissue obtained is insufficient for
a reliable histological diagnosis [13–17]. Because an endome-
trial (pre)malignancy is present in 6–23% of the women
with a failed endometrial biopsy, these patients cannot be
reassured without further more invasive investigations [14,
15].
In a previous publication, we described a multivariable
prediction model to predict the probability of a failed
endometrial biopsy in women with PMB [15]. The purpose
of the current study was to evaluate whether this model has
the potential to reduce costs for the same accuracy as the
regular diagnostic testing in women with PMB through a
cost-minimization analysis.
2. Methods
We performed a cost-minimization analysis using a model
based decision analytic approach. The aim was to evaluate
whether in women with a first episode of PMB individu-
alizing the decision to perform immediate diagnostic hys-
teroscopy rather than perform an endometrial biopsy in all
women can decrease the costs of the diagnostic work-up.This
decision was based on the probability of a failed endometrial
biopsy, estimated with a clinical prediction model based on
patient characteristics. Recently, we developed such a model
in women presenting with postmenopausal bleeding and
an endometrial thickness of more than 4.0mm. Details on
model development are presented in the original paper [15].
In short, data of 356 women with PMB were included in
a multivariable regression analysis. Characteristics satisfying
the criteria for inclusion in the model were time since
menopause, hypertension, endometrial thickness (catego-
rized), and nulliparity. A failed endometrial biopsy was
defined as a technical failure or insufficient number of tissue
for a reliable diagnosis. Endometrial biopsy failed in 44.4%
(95% CI 39.3 to 49.6%) of the women (158/356). The dis-
criminative capacity of the model was assessed with the area
under the receiver operator characteristic (ROC) curve and
was 0.64 (95% CI 0.58 to 0.70). The calibration of the model
was good indicating that there was high agreement between
the predicted probabilities and the observed proportion of
failed endometrial biopsies.
2.1. Cost Minimization Analysis. The cost minimization anal-
ysis compared two diagnostic strategies: (I) attempting office
endometrial biopsy in all women and performing outpatient
hysteroscopy after failed biopsy and (II) decision for endome-
trial biopsy or direct referral to outpatient hysteroscopy based
on model based probability of a failed biopsy. The diagnostic
strategies are represented in Figure 1. The sensitivity and
specificity associated with different failure rate cut-offs were
calculated in the prospective cohort. As the individualized
strategy may become cost saving at a certain cut-off, a
threshold analysis was performed to identify this cut-off.
Table 1: Model input: direct medical costs.
Variable Cost (C) Range (C)
Outpatient appointment (first visit) 129 60–250
Outpatient appointment (follow-up visit) 65 30–135
Outpatient appointment (hysteroscopy
clinic visit) 194 100–400
Hysteroscopy including endometrial
biopsy and pathologists fee, maintenance,
and sterilization
144 70–250
Endometrial biopsy during outpatient
visit including pathologists fee 89 40–150
2.1.1. Assumptions. Outpatient hysteroscopy with biopsy was
assumed to be the gold standard with a 100% correct diagno-
sis. Furthermore, it was assumed that in all women diagnostic
investigations would be continued until adequate material
for a histological diagnosis is obtained. Hence, all women in
whom endometrial biopsy failed are subsequently referred
to outpatient hysteroscopy with biopsy. With both strategies,
material for diagnosis will be obtained in all patients.
2.1.2. Costs. The analysis was conducted from a health care
provider’s perspective and included direct medical costs in
euros (Table 1). Unit costs were based on Dutch reference
prices [18] and local cost calculations (Academic Medical
Center, Amsterdam). Costs for outpatient hysteroscopy were
estimated per procedure and included costs for maintenance,
disinfection, and sterilization. Costs for an outpatient clinic
visit included the specialist fee, costs for the assisting person-
nel, and overhead costs.
2.2. Statistical Analysis. Analyses were performed using
TreeAgePro 2008 (TreeAge Software Inc., Williamstown,
MA). In addition to the base-case analysis, evaluating the
results for the most likely estimates of model parameters,
one-way sensitivity analyses were carried out to explore the
robustness of the results for uncertainty in these parameters,
including model accuracy, incidence of failure, and unit cost
estimates.
3. Results
3.1. Base Case Analysis. In this economic analysis, expected
costs for the two diagnostic strategies were compared. As
endometrial biopsy failed in 44% of the patients in the cohort
study, this percentage was assumed in the assessment of strat-
egy I. In the prospective cohort, the predicted probability of
failure varied between 22 and 73%. The threshold analysis to
identify a failure cut-off percentage was performed. Because
in the prospective cohort the predicted probability of failure
varied between 22 and 73%, we analyzed 50, 55, 60, 65,
and 70% cut-offs. For these different failure probability cut-
offs, sensitivity and specificity were calculated.The associated
true positive rate and false negative rate for each cut-off
were inserted in the cost-effectiveness model to calculate the
expected costs for the two strategies and the cost differences
between strategies.The results of these analyses are presented
in Table 2.
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Figure 1: Flowchart representing the two diagnostic strategies.
In the base-case analysis, expected costs for strategy I
were C 460 per patient; the costs for strategy II ranged from
C 457 for a 65% cut-off to C 475 for a 55% cut-off, implicating
that, only at a 65%predicted failure cut-off, strategy II appears
to be less costly than strategy I. At this threshold, strategy II
would result in a saving of C 3 per patient presenting with
PMB (Table 2).
3.2. Sensitivity Analyses. All sensitivity analyses performed
for cost variables to explore robustness of the results for
uncertainties in cost-estimates showed results consistent with
the base case analysis. For a cut-off value of 65%, the minimal
expected cost-difference between strategy I and strategy II
was C 1 and the maximum expected cost-difference was C
5 (Table 3). A sensitivity analysis varying the percentage of
failure showed that strategy I is always cost-effective if the
failure rate of endometrial biopsies is 25% or less.
4. Discussion
In this study a cost-minimization analysis was performed
to investigate the potential for cost savings of selecting
women with a first episode of PMB for endometrial biopsy
or hysteroscopy based on the predicted probability of a failed
biopsy. At a cut-off of 65% predicted failure rate, this possibly
results in a very small saving per patient presenting with
PMB.
The strength of this analysis is the new approach to the
problem of a failed endometrial biopsy in women with PMB.
Increasingly, prediction models are developed for clinical
practice. We performed an analysis to evaluate the cost-
effectiveness of the model: this is an essential step before a
model can be implemented in clinical practice.
A limitation of our study is the model based approach.
As for all model based studies, the validity of the model
depends on themodel input parameters and assumptions.We
assumed that a hysteroscopy, as golden standard diagnostic
procedure, would always succeed and lead to a diagnosis;
in reality this is not always the case. We also assumed that
an outpatient endometrial biopsy, if successful, would lead
to an accurate diagnosis. In reality, the detection rate of
endometrial cancer in womenwith postmenopausal bleeding
is 99.6% for the Pipelle device (Pipelle de Cornier, Paris,
France) and 97.1% for the Vabra device (Berkeley Medevices,
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Table 2: Accuracy, uncertainty, and impact of cut-off values for predicted probability of a failed endometrial biopsy in women with
postmenopausal bleeding and endometrial thickness of >4.0mm.
Cut-off failure






(strategy II − strategy
I) (C)
50% 0.30 (0.25–0.35) 0.86 (0.81–0.91) 460 472 12
55% 0.21 (0.16–0.26) 0.92 (0.87–0.97) 460 475 15
60% 0.14 (0.09–0.19) 0.96 (0.91–1.0) 460 460 0
65% 0.075 (0.025–0.125) 0.99 (0.94–1.0) 460 457 −3
70% 0.008 (0.0–0.06) 0.99 (0.94–1.0) 460 462 2
Table 3: Sensitivity analysis: minimum and maximum expected costs and cost-difference for 65% cut-off value.
Variable Strategy I Strategy II Difference
Minimum (C) Maximum (C) Minimum (C) Maximum (C) Minimum (C) Maximum (C)
Outpatient appointment
(first visit) 391 581 388 578 3 3
Outpatient appointment
(follow-up visit) 409 561 408 556 1 5
Outpatient appointment
(hysteroscopy clinic visit) 418 550 415 549 3 1
Hysteroscopy 427 506 424 504 3 2
Endometrial biopsy 411 521 410 516 1 5
Inc., Richmond, CA,USA) [11]. Another possible limitation is
the costs used in our analyses. Because precise economic data
are not available, we used the best available data that could
be acquired from national and local sources [18]. To evaluate
the impact of our cost estimates and ranges, we performed
sensitivity analyses.The results were consistent across various
analyses, implying that the conclusions are generalizable to
other clinics where costs may be somewhat different. In
the Netherlands, the transvaginal ultrasound is performed
by the consulting gynecologist. In some other countries, a
transvaginal ultrasound is a diagnostic procedure that has to
be ordered separately and incurs extra costs.These differences
should be taken into account when applying the results of
our study to countries with a different health care system.
The work-up in our model conformed to recommendations
in the Dutch national guideline on the work-up for women
with PMB [7].
Clark and colleagues investigated the cost-effectiveness
of initial diagnostic strategies for women with PMB. Their
conclusionwas that, depending on the prevalence of endome-
trial malignancy, an endometrial biopsy after endometrial
thickness measurement with a cut-off of 4 or 5mm was the
most cost-effective strategy [12]. In this analysis, however,
the probability of a failed endometrial biopsy was only 12%
and, in contrast to our current study, this probability was
independent of patient characteristics.
Because the implementation of a prediction model in
clinical practice is time consuming, the model should be
easy applicable and the benefits in terms of cost-effectiveness
should be substantial. In view of the results of our study,
in our health care system, the potential value of using
the prediction model for a failed endometrial biopsy in
women presenting with PMB appears to be limited and not
contributing to a more efficient use of health care resources.
Based on the current study, we recommend outpatient
endometrial biopsy for all women presenting with a first
episode of PMB and an endometrial thickness of more than
4.0mm. Patients in whom endometrial biopsy fails have 6–
23% risk of an endometrial (pre)malignancy and cannot
be reassured without further testing [14, 15]. In case of a
failed endometrial biopsy, a hysteroscopy with guided biopsy
should be performed. Future research should, to increase
the efficiency of the diagnostic work-up for women with
PMB, focus on decreasing the number of failed endometrial
biopsies.
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